Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study.

Alexander A NavariniJ C PrinzAkimichi Morita Tsen Fang TsaiM-A ViguierL LiC ThomaM SivalingamM G Lebwohl

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

Patients with a GPP flare treated with spesolimab achieved improvements in PROs by Week 1, which were sustained for 12 weeks, and achieved MCIDs as early as Week 1.

Keyphrases

patient reported outcomes
randomized controlled trial
clinical trial
gestational age
newly diagnosed
study protocol
preterm birth
double blind